Opinion|Videos|May 5, 2025
Emerging Molecular Biomarkers in Ovarian Cancer
Author(s)Bradley J. Monk, MD, FACS, FACOG
A panelist discusses how multiple molecular biomarkers beyond BRCA and homologous recombination deficiency (HRD) testing are emerging as important for guiding ovarian cancer therapy, including microsatellite instability (MSI), tumor mutational burden (TMB), HER2, p53, KRAS, and CCNE amplification.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Emerging Molecular Biomarkers Beyond BRCA/HRD
Several important biomarkers guide ovarian cancer treatment beyond BRCA and HRD:
Tumor-agnostic biomarkers:
- MSI/mismatch repair deficiency and TMB: Predict response to immunotherapy
- HER2 (immunohistochemistry): Approved April 2024 for trastuzumab deruxtecan (FDA approved for 3+ expression; National Comprehensive Cancer Network recommends for 2+ also)
Diagnostic and predictive biomarkers:
- p53: Distinguishes high-grade from low-grade serous ovarian cancer
- KRAS: Expected to become an integrated biomarker for upcoming MEK/FAK inhibitor combination therapy in low-grade serous ovarian cancer
- CCNE1 amplification: Mutually exclusive with BRCA mutations, associated with platinum resistance, with targeted therapies in development
The field continues to advance through collaborative research networks, including GOG Foundation and ENGOT, developing biomarker-directed treatments for gynecologic cancers.
Advertisement
Related to this article
Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.
From taladegib to admilparant and inhaled treprostinil, here are the key 2026 advances in idiopathic pulmonary fibrosis care.
HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.
Real-world data show antifibrotic dose reductions in IPF were not significantly linked to faster disease progression vs staying on full dose.
Naim Alkhouri, MD, on real-world resmetirom results, when biopsy is still needed, choosing a GLP-1 or resmetirom, and access barriers in MASH
A post hoc ASPEN analysis links darker sputum to higher protease activity in bronchiectasis.
At an AJMC Stakeholder Interchange in Houston, leukemia specialists from academic centers and community practices said menin inhibitors work best in combination, warned that differentiation syndrome can strike months into therapy, and described payer rules that delay access even at flagship centers.
UAB experts said new bladder cancer, myeloma, and lung cancer therapies are changing care, but access and costs remain barriers.
Advertisement
Advertisement
Trending on AJMC
1
New Data Link Cabotegravir PrEP to Few HIV Cases, Higher Adherence
2
Biosimilar Entry Should Trigger a Fresh Look at Biologic Access
3
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
4
HHS Draft Policy Eases Enforcement on 6 Compounded Peptides
5